20 patents
Utility
Compounds and Methods for Treating Tight Junction Permeability
26 Oct 23
The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy more desirable dosing schedules.
Jay P. MADAN, Balasingham RADHAKRISHNAN, Sandeep LAUMAS, Christopher PRIOR
Filed: 8 Feb 23
Utility
Methods for Treating Short Bowel Syndrome And/or High Output Ostomy
19 Oct 23
The present invention provides methods for treating short bowel syndrome and/or high output ostomy.
Patrick H. GRIFFIN, Nir BARAK, Sireesh APPAJOSYULA
Filed: 2 May 23
Utility
Oxymetazoline for the Treatment of Ano-rectal Disorders
17 Aug 23
Methods for treating fecal incontinence by administering to a subject in need thereof compositions including oxymetazoline as an active ingredient.
Nir BARAK, Howard Lawrence RICE
Filed: 25 Apr 23
Utility
Larazotide Derivatives Comprising D-amino Acids
13 Jul 23
The present invention provides compositions comprising an effective amount of a peptide having the amino acid sequence Gly-Gly-(d)Val-(d)Leu-(d)Val-(d)Gln-(d)Pro-Gly (SEQ ID NO: 6) to promote tight junction integrity, or a pharmaceutically acceptable salt thereof, and a pharmaceutically-acceptable carrier.
Jay P. MADAN, Balasingham RADHAKRISHNAN, Sandeep LAUMAS, Christopher PRIOR, Anthony BLIKSLAGER, Patrick H. GRIFFIN, Nir BARAK, Sireesh APPAJOSYULA
Filed: 15 Apr 21
Utility
Compounds and methods for treating tight junction permeabtility
21 Mar 23
The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy and more desirable dosing schedules.
Jay P. Madan, Balasingham Radhakrishnan, Sandeep Laumas, Christopher Prior
Filed: 25 Feb 19
Utility
Larazotide Formulations
20 Oct 22
The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations.
Balasingham RADHAKRISHNAN, Jay P. MADAN, Gary F. MUSSO
Filed: 14 Aug 20
Utility
Compositions and Methods for Treating Ulcerative Colitis
25 Aug 22
The invention, in various aspects and embodiments, provides compositions and methods for treating or managing ulcerative colitis (UC) (including mild or moderate UC), including intestinal and extraintestinal symptoms, including but not limited to arthritis.
Nir BARAK, Sireesh APPAJOSYULA, Patrick H. GRIFFIN
Filed: 3 Aug 21
Utility
Composition and Methods for Rectal Delivery of 4-AAPA and 5-ASA Compounds
12 May 22
The invention, in various aspects and embodiments, provides compositions and methods for treating or preventing inflammation of the lower gastrointestinal tract.
Balasingham RADHAKRISHNAN, JAY P. MADAN, Sireesh APPAJOSYULA, Sandeep LAUMAS
Filed: 13 Apr 20
Utility
Treatment of cancer with larazotide derivatives in combination with immune checkpoint inhibitors
22 Mar 22
The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy.
Jay Madan, Sandeep Laumas
Filed: 23 Apr 21
Utility
Compositions and Methods for Treating Sjogren's Syndrome
17 Feb 22
The present invention provides compositions and methods for treating Sjogren's syndrome (SS), including primary or secondary SS, as well as methods for preventing clinical disease in patients at risk of developing clinical SS.
Jay P. MADAN, Kathy L. SIVILS, Umesh DESHMUKH, Balasingham RADHAKRISHNAN, Kendyle WOODARD, Harini BAGAVANT
Filed: 3 Nov 21
Utility
Compositions and Methods for Potentiating Immune Checkpoint Inhibitor Therapy
25 Nov 21
The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy.
Jay MADAN, Sandeep LAUMAS
Filed: 19 Mar 19
Utility
Compositions and Methods for Treating Disease Associated with Permeability of Intestinal Epithelium
30 Sep 21
The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability.
JAY MADAN, ANTHONY BLIKSLAGER, Sandeep Laumas
Filed: 10 Jun 21
Utility
Compositions and Methods for Potentiating Immune Checkpoint Inhibitor Therapy
5 Aug 21
The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy.
Jay MADAN, Sandeep LAUMAS
Filed: 23 Apr 21
Utility
Compositions and methods for treating disease associated with permeability of intestinal epithelium
13 Jul 21
The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability.
Jay P. Madan, Anthony Blikslager, Sandeep Laumas
Filed: 12 Feb 18
Utility
Compositions and Methods for Potentiating Immune Checkpoint Inhibitor Therapy
10 Jun 21
The present invention provides compositions and methods for treating a patient having cancer, as well as methods for potentiating an immune checkpoint inhibitor therapy.
Jay MADAN, Sandeep LAUMAS
Filed: 10 Feb 21
Utility
Compositions and Methods for Treating or Preventing Hyperglycemia, Insulin Resistance, and Associated Organ Damage
11 Mar 21
The present invention provides compositions and methods for treating hyperglycemia, insulin resistance, and associated organ damage, including in some embodiments diabetes mellitus (type 1 or 2), metabolic syndrome, obesity, fatty liver diseases, or kidney disease.
Christopher PRIOR, Sandeep LAUMAS
Filed: 8 Apr 19
Utility
Compositions and Methods for Treating or Preventing Intestinal Paracellular Permeability
4 Feb 21
The present invention provides methods and compositions for maintaining and improving the integrity of gastrointestinal epithelial tight junctions, thereby helping to maintain healthy paracellular permeability of the GI epithelium.
Jay P. MADAN
Filed: 25 Feb 19
Utility
Compounds and Methods for Treating Tight Junction Permeability
16 Dec 20
The present invention provides Larazotide derivative compositions that resist protease degradation, and in various embodiments, do not demonstrate an inverse dose response, and/or can be delivered at higher doses without loss of potency or efficacy, thereby allowing improved therapy more desirable dosing schedules.
Jay P. MADAN, Balasingham RADHAKRISHNAN, Sandeep LAUMAS, Christopher PRIOR
Filed: 24 Feb 19
Utility
Compositions and Methods for Treating Disease Associated with Permeability of Intestinal Epithelium
27 Nov 19
The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability.
JAY MADAN, ANTHONY BLIKSLAGER
Filed: 11 Feb 18
Utility
Compositions and Methods for Treating or Preventing Environmental Enteropathy
27 Nov 19
The present invention provides compositions and methods for treating or preventing environmental enteropathy and associated intestinal damage.
JAY MADAN, OSCAR COLIN STINE
Filed: 11 Feb 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first